Evaluation of second-line response to targeted therapy following progression on first-line cediranib, an oral pan-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), in advanced renal cell carcinoma (RCC). Conference Paper uri icon


  • Richter, S
  • Gan, HK
  • MacKenzie, MJ
  • Hotte, SJ
  • Mukherjee, SD
  • Kollmannsberger, CK
  • Ivy, SP
  • Fernandes, K
  • Halford, R
  • Massey, C
  • Wang, L
  • Moore, MJ
  • Sridhar, SS

publication date

  • May 20, 2011